These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 15605446)

  • 1. Zero-order release of theophylline from a core-in-cup tablet in sequenced simulated gastric and intestinal fluid.
    Danckwerts MP; van der Watt JG; Moodley I
    Drug Dev Ind Pharm; 1998 Feb; 24(2):163-7. PubMed ID: 15605446
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimization and development of a core-in-cup tablet for modulated release of theophylline in simulated gastrointestinal fluids.
    Danckwerts MP
    Drug Dev Ind Pharm; 2000 Jul; 26(7):767-72. PubMed ID: 10872096
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro and in vivo sustained-release characteristics of theophylline matrix tablets and novel cluster tablets.
    Hayashi T; Kanbe H; Okada M; Kawase I; Ikeda Y; Onuki Y; Kaneko T; Sonobe T
    Int J Pharm; 2007 Aug; 341(1-2):105-13. PubMed ID: 17512147
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design and evaluation of a controlled-release theophylline tablet. Preliminary communication.
    Gai MN; Pezoa R; Corbeaux J; Arancibia A
    Farmaco; 1989 Nov; 44(11):1119-26. PubMed ID: 2701966
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic evaluation in dogs of theophylline in a novel zero-order release core-in-cup tablet.
    Danckwerts MP; van der Watt JG; Moodley I
    Biopharm Drug Dispos; 1998 Nov; 19(8):517-22. PubMed ID: 9840213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of an aliphatic polyurethane as a microsphere matrix for sustained theophylline delivery.
    Subhaga CS; Ravi KG; Sunny MC; Jayakrishnan A
    J Microencapsul; 1995; 12(6):617-25. PubMed ID: 8558384
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Investigation of coated whey protein/alginate beads as sustained release dosage form in simulated gastrointestinal environment.
    Hébrard G; Hoffart V; Cardot JM; Subirade M; Alric M; Beyssac E
    Drug Dev Ind Pharm; 2009 Sep; 35(9):1103-12. PubMed ID: 19365776
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Xanthan and galactomannan (from M. scabrella) matrix tablets for oral controlled delivery of theophylline.
    Vendruscolo CW; Andreazza IF; Ganter JL; Ferrero C; Bresolin TM
    Int J Pharm; 2005 May; 296(1-2):1-11. PubMed ID: 15885450
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparative study of dissolution characteristics of polymeric and wax granulations of theophylline and their tablets.
    Uhumwangho MU; Okor RS
    Pak J Pharm Sci; 2008 Jul; 21(3):230-6. PubMed ID: 18614417
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the fluid uptake kinetics and drug release from gellan gum tablets containing metronidazole.
    Emeje MO; Franklin-Ude PI; Ofoefule SI
    Int J Biol Macromol; 2010 Aug; 47(2):158-63. PubMed ID: 20471410
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Studies of chitosan/Kollicoat SR 30D film-coated tablets for colonic drug delivery.
    Fan LF; He W; Chang YZ; Xiang B; Du Q; Wang F; Qin M; Cao DY
    Int J Pharm; 2009 Jun; 375(1-2):8-15. PubMed ID: 19457627
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In-vitro and in-vivo evaluation of enteric-coated starch-based pellets prepared via extrusion/spheronisation.
    Dukić-Ott A; De Beer T; Remon JP; Baeyens W; Foreman P; Vervaet C
    Eur J Pharm Biopharm; 2008 Sep; 70(1):302-12. PubMed ID: 18579353
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Per-oral controlled release dosage form of theophylline using soybean protein.
    Machida Y; Tokumura T; Nagai T
    Drug Des Deliv; 1987 Feb; 1(3):187-92. PubMed ID: 3509332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Controlled release of theophylline from inert matrices: effect of channeling material on release rate.
    Ghaly ES; Malavé MI; Rivera WJ; Martí A
    P R Health Sci J; 1993 Dec; 12(4):255-8. PubMed ID: 8140202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of acryclic and metacrylic acid derivatives as sustained release matrices for theophylline hydrate tablets.
    Ofoefule SI; Chukwu A
    Boll Chim Farm; 1999 Nov; 138(10):526-30. PubMed ID: 10765469
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dissolution rate and transit times of technetium-99m DTPA-labeled tablets.
    Maublant JC; Sournac M; Aiache JM; Veyre A
    J Nucl Med; 1987 Jul; 28(7):1199-203. PubMed ID: 3298574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The influence of protonation ratio on properties of carboxymethyl starch excipient at various substitution degrees: Structural insights and drug release kinetics.
    Assaad E; Mateescu MA
    Int J Pharm; 2010 Jul; 394(1-2):75-84. PubMed ID: 20435114
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of honey locust (Gleditsia triacanthos Linn.) gum as sustaining material in tablet dosage forms.
    Uner M; Altinkurt T
    Farmaco; 2004 Jul; 59(7):567-73. PubMed ID: 15231434
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Thermoplastic granulation as an alternative method for the preparation of hydrophilic-lipophilic oral matriix tablets].
    Dvorácková K; Rabisková M; Masteiková R; Vocilková L
    Ceska Slov Farm; 2007 Jun; 56(3):129-34. PubMed ID: 17867525
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhancement of dissolution rate of piroxicam using liquisolid compacts.
    Javadzadeh Y; Siahi-Shadbad MR; Barzegar-Jalali M; Nokhodchi A
    Farmaco; 2005 Apr; 60(4):361-5. PubMed ID: 15848213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.